Xinwei Kuang
Overview
Explore the profile of Xinwei Kuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, et al.
Nat Genet
. 2025 Mar;
57(3):680-693.
PMID: 40069506
Tumors undergo metabolic reprogramming to meet the energetic, synthetic and redox demands essential for malignancy, often characterized by increased glycolysis and lactate production. However, the role of mitochondrial metabolism in...
2.
Xu Y, Jiang Z, Kuang X, Chen X, Liu H
J Med Internet Res
. 2022 Jun;
24(6):e32728.
PMID: 35759331
Background: Melanoma is one of the most life-threatening skin cancers; immune checkpoint blockade is widely used in the treatment of melanoma because of its remarkable efficacy. Objective: This study aimed...
3.
Zhu L, Kuang X, Zhang G, Liang L, Liu D, Hu B, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577504
Background: Immune checkpoint inhibitors (ICIs) have been increasingly used in patients with various cancers and have shown efficient therapeutic outcomes. However, fewer than 40% of cases across multiple cancer types...
4.
Kuang X, Wang Z, Luo Z, He Z, Liang L, Gao Q, et al.
J Colloid Interface Sci
. 2022 Feb;
616:189-200.
PMID: 35203032
Immune checkpoint blockade (ICB) therapy, represented by programmed cell death protein 1 (PD-1) and its ligand (PD-L1) monoclonal antibodies (mAbs), has shown an obvious benefit for melanoma immunotherapy, but the...
5.
Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, et al.
Innovation (Camb)
. 2022 Jan;
3(1):100194.
PMID: 34977836
Immune checkpoint blockade (ICB) therapies exhibit substantial clinical benefit in different cancers, but relatively low response rates in the majority of patients highlight the need to understand mutual relationships among...
6.
Xiang M, Liang L, Kuang X, Xie Z, Liu J, Zhao S, et al.
J Cell Mol Med
. 2021 Sep;
25(19):9228-9240.
PMID: 34469054
Melanoma is a highly aggressive type of skin cancer. The development of diverse resistance mechanisms and severe adverse effects significantly limit the efficiency of current therapeutic approaches. Identification of the...
7.
Li H, Kuang X, Liang L, Ye Y, Zhang Y, Li J, et al.
Adv Sci (Weinh)
. 2021 Jan;
8(2):2001596.
PMID: 33510997
Immune checkpoints blockades have shown promising clinical effects in various malignancies, but the overall response rate is low. Here, the immune features are comprehensively characterized in >10 000 cancer patients...
8.
Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, et al.
Genome Med
. 2020 Sep;
12(1):83.
PMID: 32988398
Background: Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a small proportion of cancer patients. Recent studies have...
9.
Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al.
Cancer Cell
. 2020 Mar;
37(3):324-339.e8.
PMID: 32183950
Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the...
10.
Tang Z, Ye W, Chen H, Kuang X, Guo J, Xiang M, et al.
Purinergic Signal
. 2019 Sep;
15(4):423-438.
PMID: 31493132
Purines, among most influential molecules, are reported to have essential biological function by regulating various cell types. A large number of studies have led to the discovery of many biological...